Eltrombopag Tablet
NDC 70771-1925
Product Information
Eltrombopag is a ANDA-approved product labeled by Zydus Lifesciences Limited. This medication is typically used as a breast cancer resistance protein inhibitors [moa]. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 70771-1925 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
I Code Structure Chart
Product Details
What is NDC 70771-1925?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ELTROMBOPAG OLAMINE (UNII: 4U07F515LG)
- ELTROMBOPAG (UNII: S56D65XJ9G) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)
- MICROCRYSTALLINE CELLULOSE 101 (UNII: 7T9FYH5QMK)
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- POVIDONE K30 (UNII: U725QWY32X)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
- SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- XYLITOL (UNII: VCQ006KQ1E)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1245001 - eltrombopag 12.5 MG Oral Tablet
- RxCUI: 1245001 - eltrombopag (as eltrombopag olamine) 12.5 MG Oral Tablet
- RxCUI: 825421 - eltrombopag 25 MG Oral Tablet
- RxCUI: 825421 - eltrombopag (as eltrombopag olamine) 25 MG Oral Tablet
- RxCUI: 825427 - eltrombopag 50 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Increased Megakaryocyte Maturation - [PE] (Physiologic Effect)
- Increased Platelet Production - [PE] (Physiologic Effect)
- Organic Anion Transporting Polypeptide 1B1 Inhibitors - [MoA] (Mechanism of Action)
- Thrombopoietin Receptor Agonist - [EPC] (Established Pharmacologic Class)
- Thrombopoietin Receptor Agonists - [MoA] (Mechanism of Action)
- UGT1A1 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A3 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A4 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A6 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A9 Inhibitors - [MoA] (Mechanism of Action)
- UGT2B15 Inhibitors - [MoA] (Mechanism of Action)
- UGT2B7 Inhibitors - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.